These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 31166752)

  • 1. Comparison of
    Hunt KN; Conners AL; Goetz MP; O'Connor MK; Suman V; Kalari K; Weinshilboum R; Wang L; Carter J; McLaughlin S; Aspitia AM; Gray R; Northfelt D; Boughey JC
    AJR Am J Roentgenol; 2019 Oct; 213(4):932-943. PubMed ID: 31166752
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnostic Performance of MRI, Molecular Breast Imaging, and Contrast-enhanced Mammography in Women with Newly Diagnosed Breast Cancer.
    Sumkin JH; Berg WA; Carter GJ; Bandos AI; Chough DM; Ganott MA; Hakim CM; Kelly AE; Zuley ML; Houshmand G; Anello MI; Gur D
    Radiology; 2019 Dec; 293(3):531-540. PubMed ID: 31660801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 99mTc-MIBI scintigraphy as a functional method for the evaluation of multidrug resistance in breast cancer patients.
    Sergieva SB; Timcheva KV; Hadjiolov ND
    J BUON; 2006; 11(1):61-8. PubMed ID: 17318954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 99mTc-sestamibi using a direct conversion molecular breast imaging system to assess tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer.
    Mitchell D; Hruska CB; Boughey JC; Wahner-Roedler DL; Jones KN; Tortorelli C; Conners AL; O'Connor MK
    Clin Nucl Med; 2013 Dec; 38(12):949-56. PubMed ID: 24152645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.
    Scheel JR; Kim E; Partridge SC; Lehman CD; Rosen MA; Bernreuter WK; Pisano ED; Marques HS; Morris EA; Weatherall PT; Polin SM; Newstead GM; Esserman LJ; Schnall MD; Hylton NM;
    AJR Am J Roentgenol; 2018 Jun; 210(6):1376-1385. PubMed ID: 29708782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Technetium-99m Sestamibi Imaging Able to Predict Pathologic Nonresponse to Neoadjuvant Chemotherapy in Breast Cancer? A Meta-analysis Evaluating Current Use and Shortcomings.
    Collarino A; de Koster EJ; Valdés Olmos RA; de Geus-Oei LF; Pereira Arias-Bouda LM
    Clin Breast Cancer; 2018 Feb; 18(1):9-18. PubMed ID: 28728876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
    Choi BB; Kim SH
    Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast-Specific Gamma Imaging Versus MRI: Comparing the Diagnostic Performance in Assessing Treatment Response After Neoadjuvant Chemotherapy in Patients With Breast Cancer.
    Kim S; Plemmons J; Hoang K; Chaudhuri D; Kelley A; Cunningham T; Hoefer R
    AJR Am J Roentgenol; 2019 Mar; 212(3):696-705. PubMed ID: 30620672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
    Ko ES; Han BK; Kim RB; Ko EY; Shin JH; Hahn SY; Nam SJ; Lee JE; Lee SK; Im YH; Park YH
    Ann Surg Oncol; 2013 Aug; 20(8):2562-8. PubMed ID: 23463090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of (99m)Tc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy.
    Sciuto R; Pasqualoni R; Bergomi S; Petrilli G; Vici P; Belli F; Botti C; Mottolese M; Maini CL
    J Nucl Med; 2002 Jun; 43(6):745-51. PubMed ID: 12050317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold.
    Kim Y; Sim SH; Park B; Lee KS; Chae IH; Park IH; Kwon Y; Jung SY; Lee S; Ko K; Kang HS; Lee CW; Lee ES
    Clin Breast Cancer; 2018 Dec; 18(6):459-467.e1. PubMed ID: 29954674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.
    Goorts B; Dreuning KMA; Houwers JB; Kooreman LFS; Boerma EG; Mann RM; Lobbes MBI; Smidt ML
    Breast Cancer Res; 2018 Apr; 20(1):34. PubMed ID: 29669584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer: monitoring response to neoadjuvant chemotherapy using Tc-99m sestamibi scintimammography.
    Tiling R; Kessler M; Untch M; Sommer H; Linke R; Brinkbäumer K; Hahn K
    Onkologie; 2003 Feb; 26(1):27-31. PubMed ID: 12624514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?
    Andrade WP; Lima EN; Osório CA; do Socorro Maciel M; Baiocchi G; Bitencourt AG; Fanelli MF; Damascena AS; Soares FA
    Eur J Surg Oncol; 2013 Dec; 39(12):1358-63. PubMed ID: 24120422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy.
    Akazawa K; Tamaki Y; Taguchi T; Tanji Y; Miyoshi Y; Kim SJ; Ueda S; Yanagisawa T; Sato Y; Tamura S; Noguchi S
    Breast J; 2006; 12(2):130-7. PubMed ID: 16509837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of Magnetic Resonance Imaging-Guided Biopsy to Verify Breast Cancer Pathologic Complete Response After Neoadjuvant Chemotherapy: A Nonrandomized Controlled Trial.
    Sutton EJ; Braunstein LZ; El-Tamer MB; Brogi E; Hughes M; Bryce Y; Gluskin JS; Powell S; Woosley A; Tadros A; Sevilimedu V; Martinez DF; Toni L; Smelianskaia O; Nyman CG; Razavi P; Norton L; Fung MM; Sedorovich JD; Sacchini V; Morris EA
    JAMA Netw Open; 2021 Jan; 4(1):e2034045. PubMed ID: 33449096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.
    Ciarmiello A; Del Vecchio S; Silvestro P; Potena MI; Carriero MV; Thomas R; Botti G; D'Aiuto G; Salvatore M
    J Clin Oncol; 1998 May; 16(5):1677-83. PubMed ID: 9586878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of molecular breast imaging to assess response in women undergoing neoadjuvant therapy for breast cancer: a pilot study.
    Wahner-Roedler DL; Boughey JC; Hruska CB; Chen B; Rhodes DJ; Tortorelli CL; Maxwell RW; Cha SS; O'Connor MK
    Clin Nucl Med; 2012 Apr; 37(4):344-50. PubMed ID: 22391702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of molecular breast imaging in predicting complete tumor response to treatment and residual tumor extent following neoadjuvant therapy.
    Nuvoli S; Galassi S; Gelo I; Rocchitta G; Fancellu A; Serra PA; Madeddu G; Spanu A
    Oncol Rep; 2018 May; 39(5):2055-2062. PubMed ID: 29512735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.